| Value | ₹74.34 Cr |
|---|
BSE filing, NSE: TRIMURTHI. Summary written from the filing by ALFA Finder's alert engine.
Novelix Pharmaceuticals Ltd: key numbers
- Share price
- ₹61.41
- Market cap
- ₹108.2 Cr
- Revenue (annual)
- ₹132.3 Cr
- Net profit (annual)
- ₹2.56 Cr
- P/E (TTM)
- 29.8×Sector 61.5×
- Promoter holding
- 54.29%+3.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novelix Pharmaceuticals Ltd
All →Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Novelix Pharmaceuticals Management Change
Novelix Pharmaceuticals announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director, approved by shareholders at the company's 32nd Annual General Meeting.
Novelix Pharmaceuticals Annual General Meeting
Novelix Pharmaceuticals held its 32nd Annual General Meeting on 30th September, 2026, transacting ordinary and special business items via e-voting and video conferencing.
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.
Novelix Pharmaceuticals Annual Report
Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.
Novelix Pharmaceuticals Annual General Meeting
Novelix Pharmaceuticals Limited will hold its 32nd Annual General Meeting on September 30, 2026. The company has fixed September 23, 2026, as the cut-off date for e-voting.
Other capital structure change announcements
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr